<DOC>
	<DOCNO>NCT00499928</DOCNO>
	<brief_summary>This study examine biological fate radioactive SB-751689 administer healthy male healthy postmenopausal woman . Subjects receive single oral dose radioactive SB-751689 . Excreta blood sample take course 7 day . This study help determine major route elimination SB-751689 human . It also provide sample ( blood , plasma , urine , stool ) analysis metabolite , .</brief_summary>
	<brief_title>A Study To Investigate The Metabolism And Excretion Of 14C SB-751689 Given To Healthy Males And Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<criteria>Healthy adult male age 35 65 year , inclusive , healthy ambulatory postmenopausal woman define amenorrheic least 2 year 40 65 year age , inclusive , screen FSH level consistent menopause . Healthy postmenopausal woman , age 40 50 year , inclusive , must also documented history bilateral oophorectomy ( without hysterectomy ) least 6 week postsurgery . ) Nonsmokers Body weight &gt; = 50 kg BMI within range 19 32 kg/m2 A history regular bowel movement Capable give write informed consent Any clinically relevant biological physical abnormality find report screening , opinion investigator , clinically significant would preclude safe participation study QTc interval &gt; 450 msec screen Positive urine drug screen screen Positive urine test alcohol predose Positive HIV screen Chronic hepatitis B C , evidence positive Hepatitis B surface antigen Hepatitis C antibody Urinary cotinine level indicative smoking screen History smoking use nicotine containing product within one year study &gt; 10 packyear history smoke overall History regular alcohol consumption exceed 7 units/week woman 14 units/week men within 6 month screen History drug abuse within 6 month study Participation clinical study receive drug new chemical entity 30 day 5 halflives , twice duration biological effect drug prior first dose current study medication Exposure four new chemical entity within 12 month prior first dose day Subjects receive total body radiation dose great 5.0 mSv exposure significant radiation 12 month prior study Radiation exposure previous 3 year period 10 mSv subject expose ionize radiation background result work radiation category A worker result research study may involve . Clinical exposure include Condition could interfere accurate assessment recovery radiocarbon [ 14C ] Use prescription nonprescription drug include antacid , include vitamin , herbal dietary supplement within 7 day prior first dose study medication . Consumption red wine , grapefruit , grapefruit juice grapefruitcontaining product within 14 day prior first dose study medication Donation blood excess 500 mL within 56 day prior dose . Evidence renal , hepatic biliary impairment History serious gastrointestinal disease history gastrointestinal surgical procedure might affect absorption SB751689 History sensitivity study medication , component thereof history drug allergy , opinion physician responsible , contraindicate participation History clinically significant cardiovascular disease History pernicious anemia , pancreatitis , osteosarcoma kidney stone . Conditions might alter bone metabolism , include hyperparathyroidism , hypoparathyroidism , hyperthyroidism , hypothyroidism , Paget 's disease , myeloma , malabsorption , Cushing 's syndrome , hypogonadism ( male subject ) , hypocalcemia , hypercalcemia , hypophosphatemia , hypomagnesemia , hypermagnesemia , osteopetrosis , osteomalacia , recent history fracture prolong bed rest Liver function test , PTH , CPK outside reference range screen Males unwilling refrain father child study 14 day</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>SB-751689</keyword>
	<keyword>osteoporosis</keyword>
	<keyword>metabolism</keyword>
	<keyword>excretion</keyword>
</DOC>